Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autodesk Inc (ADSK) vs ClearPoint Neuro Inc (CLPT) Price & Performance

Autodesk Inc
ClearPoint Neuro Inc

Price performance

Price movement over the last 24 hours

Key statistics

Autodesk Inc vs ClearPoint Neuro Inc — how do they compare? Autodesk Inc trades at $207.59 (market cap $44.84B), while ClearPoint Neuro Inc trades at $17.4 (market cap $524.82M). The key difference: Autodesk Inc is far larger — about 85.4× ClearPoint Neuro Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.

ADSKCLPT
Market Cap
$44.84B$524.82M
Sector
TechnologyHealth
52-Week High
$326.79$29.60
52-Week Low
$187.72$8.66
Enterprise Value
$44.64B$552.81M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autodesk Inc

Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.

Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $18.00, down 3.85% with a bullish technical signal from moving averages. The company shows strong revenue growth with 25% organic device growth in Q1 2026 but continues to report significant losses, with a net income margin of -71.57%. Recent FDA clearance for the Velocity Alpha surgical drill and partnership expansion in South Korea highlight ongoing business development. Analyst sentiment remains strongly positive with 100% buy ratings, though the stock faces execution and regulatory risks.

The outlook remains speculative with high growth potential from gene therapy commercialization offset by persistent losses and cash burn. Investment opportunity lies in successful partner therapy commercialization, but risks include regulatory hurdles and the need for continued financing. The stock's valuation at 12.76x sales reflects growth expectations despite negative profitability metrics.

Returns comparison

Trailing returns across standard periods

About Autodesk Inc

Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.

Read more on ADSK

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT